Breaking AI & Tech News Analyzed

The risograph printer, a Japanese innovation from the 1980s, has captured the hearts of artists and creatives globally. This compact machine, produced by Riso Kagaku, allows for small print runs with a distinctive, handmade feel.Gabriella Marcella, a Scottish-Italian designer, fell in love with the risograph while studying at New York's Pratt Institute. She now curates Riso Club, a non-profit program promoting artists who use risographs. The club sends postcards featuring work from international cities, showcasing the riso community's global reach.The exhibition at Glasgow's Glue Factory Galleries celebrates the Riso Club's 100th issue with works from design heroes like Nathalie Du Pasquier and Peter Shire. Marcella hopes to demonstrate that design can be accessible, social, and connect people through print.Artists like Mari Kinovych and Kinda Ghannoum have used the risograph to showcase their cities, Kyiv and Damascus, in a unique and personal way. The risograph's political roots and ability to produce affordable prints have made it a staple in the art world.

A recent conversation with a guest at an academic function brought to light the public's desire for a simple, all-encompassing test for cancer. The guest, intrigued by the speaker's profession as an oncologist, inquired about the existence of an 'everything' test for cancer. The speaker's response was clear: no such test exists.The quest for early cancer detection is a significant goal in cancer medicine, with the aim of identifying the disease before it metastasizes and ensuring a cure. One company, Grail, launched a blood test called Galleri, which claims to detect a 'signal' shared by more than 50 types of cancer. This signal is identified through circulating DNA, minute fragments of cancer DNA present in the bloodstream.The Galleri test was marketed as a screening tool, with results indicating either a cancer signal detected or no cancer signal detected. However, the test failed to meet its primary endpoint in a large-scale trial conducted with the NHS, which aimed to determine if the test could reduce late-stage cancer diagnoses. Despite the company's claims of 'strong' results, the trial did not demonstrate a significant reduction in late-stage cancer diagnoses.The failure of the Galleri test highlights a crucial distinction between detecting more cancers and saving lives. Detecting cancer at an early stage does not necessarily translate to less invasive treatments or prolonged survival. Moreover, some cancers detected through screening may never have posed a lethal threat, leading to unnecessary interventions.For now, there is no blood test or total body scan that saves lives. Instead, the focus should be on modifying cancer risk factors, such as reducing processed foods, curbing alcohol consumption, quitting smoking, and engaging in regular exercise. These evidence-based approaches may not be as flashy as a single 'everything' test, but they have a proven impact on public health.